Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Reckitt lifts full-year forecast as mobility, vaccinations pick up

Published 26/10/2021, 07:34
Updated 26/10/2021, 10:06
© Reuters. FILE PHOTO: Products produced by Reckitt Benckiser are seen in London, Britain,  February 12, 2008.   REUTERS/Stephen Hird

By Siddharth Cavale

(Reuters) - Higher vaccination rates and improved mobility during the third quarter drove strong demand for Mucinex cough syrups and Durex condoms, Reckitt Benckiser Group said on Tuesday, prompting it to raise its full-year forecast.

That sent its shares up 5.8% in morning trading, making it the top gainer on the FTSE index.

Sales of over-the-counter medicines rose more than 20% in the quarter, driven primarily by Mucinex cough and cold remedies after a strong cold and flu season saw sales across most of its markets come in at or above 2019 levels, it said.

Improved mobility in markets including India also saw the company gain share in sexual wellness products such as Durex, Chief Executive Laxman Narasimhan said on a media call.

That drove like-for-like sales up 3.3% in the quarter, compared to the 0.7% drop analysts had expected, according to company-supplied estimates, which excluded sales from the recently completed sale of its infant nutrition business in China.

The company also raised its full-year net revenue like-for-like growth forecast to 1-3% from flat to 2% earlier, but cautioned that growth would be "softer" in the fourth quarter.

Like its peers, Reckitt said it was seeing a sharp rise in raw materials costs, which were up 10% in the quarter compared with an 8-9% rise it had estimated previously.

Chief Financial Officer Jeff Carr said he expected inflation to be "up a touch" in the fourth quarter and possibly in the low double digits in 2022, but could not estimate when these higher costs would subside.

"There will be another round of pricing we will take to offset the inflation," Narasimhan said, over and above the 1.7% hikes it took in the third quarter.

Domestos maker Unilever (LON:ULVR) last week also warned of another round of price hikes to battle fierce inflation.

© Reuters. FILE PHOTO: Products produced by Reckitt Benckiser are seen in London, Britain,  February 12, 2008.   REUTERS/Stephen Hird

Reckitt kept its adjusted operating profit margin forecast, excluding IFCN China, for the year in the range of 22.7% to 23.2%

Shares in the group were down 16% this year before the results, after hitting near-record levels in 2020.

Latest comments

can't even buy Mucinex OTC in UK
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.